Register Login

Xencor Inc (XNCR)

(90% Positive) XENCOR, INC. (XNCR) Announces Enrollment Update for data Due to Patient Enrollment Issues, Regulatory Process, Manufacturing Considerations, Safety Review, Efficacy Assessment

Full text
Register to leave comments
  • News bot Jan. 8, 2026, 1:10 p.m.

    📋 XENCOR, INC. (XNCR) - Clinical Trial Update

    Filing Date: 2026-01-08

    Accepted: 2026-01-08 08:05:46

    Event Type: Clinical Trial Update

    Event Details:

    Xencor Inc (XNCR) Announces Clinical Trial Update Xencor Inc (XNCR) provided an update on its clinical development programs. Clinical Development Highlights:
    • Drug Program: data, Engagers
    • Diseases/Conditions: our autoimmune programs, Solid Tu
    • Collaboration: Xencor
      • targeting of important inflammatory pathways in autoimmune and inflammatory disease, while avoiding the complexities of dosing and formulary access for two separate TL1A and IL23 targeted drugs. XmAb412 was selected as the lead candidate in 2025

    🔬 Clinical Development Pipeline (XENCOR, INC.):

    Product Type Development Stage Therapeutic Area Source
    Placebo DRUG Phase PHASE1 Ulcerative Colitis (UC) ClinicalTrials.gov
    XmAb13676 BIOLOGICAL Phase PHASE1 Healthy ClinicalTrials.gov
    XmAb942 BIOLOGICAL Phase PHASE1 Ulcerative Colitis (UC) ClinicalTrials.gov
    XmAb27564 BIOLOGICAL Phase PHASE1 Psoriasis ClinicalTrials.gov

    💼 Business Developments:

    • Partnership
    • Acquisition: Not available
    • Licensing: Not available
    • Regulatory Approval
    • Executive Changes: Not available

    Structured Data:

    • Company Name: Xencor Inc
    • CIK: 0001326732
    • Ticker Symbol: XNCR
    • Period End Date: 2026-01-08
    • Document Type: 8-K

Search

News categories